HomeCompareENSV vs JNJ

ENSV vs JNJ: Dividend Comparison 2026

ENSV yields 153846.15% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENSV wins by $3.570817397657267e+28M in total portfolio value
10 years
ENSV
ENSV
● Live price
153846.15%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.570817397657267e+28M
Annual income
$35,662,574,083,913,823,000,000,000,000,000,000.00
Full ENSV calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ENSV vs JNJ

📍 ENSV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENSVJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENSV + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENSV pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENSV
Annual income on $10K today (after 15% tax)
$13,076,923.08/yr
After 10yr DRIP, annual income (after tax)
$30,313,187,971,326,747,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ENSV beats the other by $30,313,187,971,326,747,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENSV + JNJ for your $10,000?

ENSV: 50%JNJ: 50%
100% JNJ50/50100% ENSV
Portfolio after 10yr
$1.7854086988286334e+28M
Annual income
$17,831,287,041,956,911,000,000,000,000,000,000.00/yr
Blended yield
99.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ENSV
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-3.8
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENSV buys
0
JNJ buys
0
No recent congressional trades found for ENSV or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENSVJNJ
Forward yield153846.15%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$3.570817397657267e+28M$30.3K
Annual income after 10y$35,662,574,083,913,823,000,000,000,000,000,000.00$4,689.40
Total dividends collected$3.5705187474861104e+28M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ENSV vs JNJ ($10,000, DRIP)

YearENSV PortfolioENSV Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$15,395,315$15,384,615.38$10,592$272.30+$15.38MENSV
2$22,152,081,017$22,135,608,029.64$11,289$357.73+$22152.07MENSV
3$29,790,603,453,124$29,766,900,726,435.82$12,123$472.89+$29790603.44MENSV
4$37,444,193,407,360,220$37,412,317,461,665,380.00$13,141$629.86+$37444193407.35MENSV
5$43,987,751,239,956,050,000$43,947,685,953,010,180,000.00$14,408$846.81+$43987751239956.04MENSV
6$48,297,311,048,679,450,000,000$48,250,244,154,852,700,000,000.00$16,021$1,151.60+$48297311048679448.00MENSV
7$49,563,274,505,183,440,000,000,000$49,511,596,382,361,350,000,000,000.00$18,122$1,588.22+$49563274505183444992.00MENSV
8$47,538,442,557,656,110,000,000,000,000$47,485,409,853,935,560,000,000,000,000.00$20,930$2,228.20+$4.753844255765611e+22MENSV
9$42,616,722,111,071,980,000,000,000,000,000$42,565,855,977,535,280,000,000,000,000,000.00$24,792$3,191.91+$4.261672211107198e+25MENSV
10$35,708,173,976,572,667,000,000,000,000,000,000$35,662,574,083,913,823,000,000,000,000,000,000.00$30,274$4,689.40+$3.570817397657267e+28MENSV

ENSV vs JNJ: Complete Analysis 2026

ENSVStock

Enservco Corporation, through its subsidiaries, provides well enhancement and fluid management services to the onshore oil and natural gas industry in the United States. It offers frac water heating, hot oiling, pressure testing, acidizing, and water hauling, as well as well site construction services. The company owns and operates a fleet of approximately 318 specialized trucks, trailers, frac tanks, and other well-site related equipment. It operates in the eastern United States region comprising the southern region of the Marcellus Shale formation and the Utica Shale formation in eastern Ohio; Rocky Mountain region consisting of western Colorado and southern Wyoming, central Wyoming, western North Dakota, and eastern Montana; and the Central United States region, including Eagle Ford Shale and East Texas Oilfield in Texas. Enservco Corporation was incorporated in 1980 and is headquartered in Longmont, Colorado.

Full ENSV Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ENSV vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENSV vs SCHDENSV vs JEPIENSV vs OENSV vs KOENSV vs MAINENSV vs ABBVENSV vs MRKENSV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.